Publications & Reports

Newsletters

LEAP Newsletter, Issue 5, October 2016
English

 

Publications

National guidelines for visceral leishmaniasis:

  • Kenya Ministry of Health guidelines (2017): PDF
  • Ethiopia Ministry of Health guidelines (2013): PDF

WHO Technical Report Series on Leishmaniasis, March 2010
PDF

 

Scientific Articles

Safety, efficacy, and pharmacokinetics of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial by Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, Sagaki P, Kimutai R, Were L, Omollo T, Egondi TW, Wasunna M, Alvar J, Dorlo TPC, and Alves F. Clinical Infectious Diseases 2018, ciy747, doi: 10.1093/cid/ciy747.
Click here to read the article

Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives by Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A, Strub-Wourgaft N, Wasunna M, Wells S, Zijlstra EE, Arana B, and Alvar J. Clinical Microbiology Reviews, August 2018
Click here to read the article

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: A population pharmacokinetic/pharmacodynamic study by Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu H, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO and Khalil EAG. Journal of Antimicrobial Chemotherapy 2017, doi:10.1093/jac/dkx283.
Click here to read the article

Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: Results from a pharmacovigilance programme by Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EAG, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M, Clinical Drug Investigation 2017, doi:10.1007/s40261-016-0481-0.
Click here to read the article

Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial by Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TPC, Musa B, Sharaf Ali MH, Elamin MY, Kirigi G, Juma R, Anke E. Kip, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EAG, Strub Wourgaft N, Alves F, Musa A. PLOS Neglected Tropical Diseases 2016, doi:10.1371/journal.pntd.0004880.
Click here to read the article

The Leishmaniasis East Africa Platform (LEAP): Strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis by Wasunna M, Musa, A, Hailu A, Khalil EAG, Olobo J, Juma R, Wells S, Alvar J, Balasegaram M. Transactions of the Royal Society of Tropical Medicine and Hygiene 2016, 1–3 doi:10.1093/trstmh/trw031.
Click here to read the article

Safety and efficacy of single dose versus multiple doses of AmBisome® for treatment of visceral leishmaniasis in Eastern Africa: A randomized trial by Khalil EAG, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid A, Dorlo TPC, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AH, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A. PLOS Neglected Tropical Diseases 2014, 8(1): e2613. doi:10.1371.
Click here to read the article

Validation of two rapid diagnostic tests for visceral leishmaniasis in Kenya by Mbui J, Wasunna M, Balasegaram M, Laussermayer A, Juma R, Njoroge Njenga S, Kirigi G, Riongoita M, de la Tour R, van Peteghem J, Omollo R, Chappuis F. PLoS Negl Trop Dis., September 2013.
Click here to read the article

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis by Dorlo TPCBalasegaram M, Beijnen JH, and de Vries PJ. Journal of Antimicrobial Chemotherapy, July 2012.
Click here to read the article

Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial by Edwards T, Omollo R, Khalil EAG, Yifru S, Musa B, Musa A, Wasunna M, Smith PG, Royce C, Ellis S, Balasegaram M, Hailu A. Trials 2011, doi:10.1186/1745-6215-12-66.
Click here to read the article

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial by Omollo R, Alexander N, Edwards T, Khalil EAG, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, PC Dorlo TPC, Ellis S, Balasegaram M and Musa AM. Trials 2011, doi:10.1186/1745-6215-12-166.
Click here to read the article

Paromomycin for the treatment of visceral leishmaniasis in Sudan: A randomized, open-label, dose-finding study by Musa A, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E. PLoS Negl Trop Dis, October 2010, 4(10):e855
Click here to read the article

Geographical variation in the response of visceral leishmaniasis to Paromomycin in East Africa: A multicentre, open-label, randomized trial by Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Muellerm, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, for the Leishmaniasis East Africa Platform (LEAP) group. PLoS Negl Trop Dis, October 2010, 4(10):e709.
Click here to read the article